SCHEMBL3276375

SCHEMBL3276375

CCOC(=O)c1c(C=O)c2ccccc2n1Cc1cccc2ccc(F)cc12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.73
MEN1 O00255 7/20 0.73
ALDH1A1 P00352 7/20 0.48
USP2 O75604 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 4/20 0.45
MAPT P10636 3/20 0.45
GAA P10253 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
LMNA P02545 4/20 0.44
ELANE P08246 2/20 0.43
NOD2 Q9HC29 1/20 0.42
NOD1 Q9Y239 1/20 0.42
POLB P06746 1/20 0.41
HCRTR1 O43613 1/20 0.41
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3275378 0.94 KMT2A (0.67) KMT2AMEN1ALDH1A1USP2SMN1; SMN2
SCHEMBL3277223 0.86 KMT2A (0.53) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL3282760 0.84 KMT2A (0.52) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL3280608 0.84 KMT2A (0.54) KMT2AMEN1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL3276110 0.84 KMT2A (0.67) KMT2AMEN1ALDH1A1USP2SMN1; SMN2
SCHEMBL3281145 0.83 MEN1 (0.51) KMT2AMEN1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL3276217 0.83 MEN1 (0.51) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL3275053 0.82 MEN1 (0.50) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL3276222 0.82 MEN1 (0.50) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL3276763 0.82 MEN1 (0.49) KMT2AMEN1ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966134-B1 NOVEL FUSED PYRROLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-03-12 EP disclosed
US-7696240-B2 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-04-13 US disclosed
EP-1966134-A1 NOVEL FUSED PYRROLE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 EP disclosed
WO-2007068621-A1 NOVEL FUSED PYRROLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-06-21 WO disclosed
US-20070142452-A1 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142452-A1 Fused pyrrole derivatives CMA1, PREP, CPA3 KMT2A 3786/4885MEN1 2461/4885ALDH1A1 827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.